Mosaic BRCA1 promoter methylation contribution in hereditary breast/ovarian cancer pedigrees
暂无分享,去创建一个
S. Vacher | I. Bièche | V. Bécette | V. Suybeng | E. Mouret‐Fourme | S. Caputo | C. Colas | L. Golmard | V. Moncoutier | Albain Chansavang | Hélène Delhomelle | Mathias Schwartz | Khadija Abidallah | J. Wong | J. Masliah-Planchon | S. Ibadioune | Marc-Henri Stern | D. Stoppa-Lyonnet | Antoine de Pauw | T. Popova
[1] P. Kristel,et al. Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers , 2023, Nature Communications.
[2] P. Nederlof,et al. Identifying the BRCA1 c.-107A > T variant in Dutch patients with a tumor BRCA1 promoter hypermethylation , 2022, Familial Cancer.
[3] P. Lønning,et al. Constitutional BRCA1 Methylation and Risk of Incident Triple-Negative Breast Cancer and High-grade Serous Ovarian Cancer , 2022, JAMA oncology.
[4] D. Easton,et al. CanRisk Tool—A Web Interface for the Prediction of Breast and Ovarian Cancer Risk and the Likelihood of Carrying Genetic Pathogenic Variants , 2020, Cancer Epidemiology, Biomarkers & Prevention.
[5] L. Saal,et al. Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers , 2020, Nature Communications.
[6] François-Clément Bidard,et al. ShallowHRD: detection of homologous recombination deficiency from shallow whole genome sequencing , 2020, Bioinform..
[7] A. Laner,et al. Analysis of 3297 individuals suggests that the pathogenic germline 5′-UTR variant BRCA1 c.-107A > T is not common in south-east Germany , 2020, Familial Cancer.
[8] A. Jakubowska,et al. BRCA1 promoter methylation in peripheral blood is associated with the risk of triple‐negative breast cancer , 2020, International journal of cancer.
[9] M. Southey,et al. Integrating DNA methylation measures to improve clinical risk assessment: are we there yet? The case of BRCA1 methylation marks to improve clinical risk assessment of breast cancer , 2020, British Journal of Cancer.
[10] M. García-Closas,et al. Correction: BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors , 2019, Genetics in Medicine.
[11] Leslie Burke,et al. Non-Coding Variants in BRCA1 and BRCA2 Genes: Potential Impact on Breast and Ovarian Cancer Predisposition , 2018, Cancers.
[12] P. Lønning,et al. BRCA1 methylation in newborns: genetic disposition, maternal transfer, environmental influence, or by chance only? , 2018, Clinical Epigenetics.
[13] Javier Santoyo-Lopez,et al. A Dominantly Inherited 5′ UTR Variant Causing Methylation-Associated Silencing of BRCA1 as a Cause of Breast and Ovarian Cancer , 2018, American journal of human genetics.
[14] A. Howell,et al. White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk , 2018, Annals of Internal Medicine.
[15] F. Couch,et al. Author Correction: The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk , 2017, npj Breast Cancer.
[16] Robert Huether,et al. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer , 2017, JAMA oncology.
[17] Steven N. Hart,et al. The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk , 2017, npj Breast Cancer.
[18] Li Zhang,et al. Association of BRCA1 promoter methylation with sporadic breast cancers: Evidence from 40 studies , 2015, Scientific Reports.
[19] Kenneth Offit,et al. Two Decades After BRCA: Setting Paradigms in Personalized Cancer Care and Prevention , 2014, Science.
[20] T. Haaf,et al. Constitutive promoter methylation of BRCA1 and RAD51C in patients with familial ovarian cancer and early-onset sporadic breast cancer , 2012, Human molecular genetics.
[21] S. Fox,et al. Constitutional Methylation of the BRCA1 Promoter Is Specifically Associated with BRCA1 Mutation-Associated Pathology in Early-Onset Breast Cancer , 2010, Cancer Prevention Research.
[22] A. Dobrovic,et al. Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation , 2007, Nucleic acids research.
[23] J. Hopper,et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.